Fairvalue-Calculator Fairvalue-Calculator
EN DE

Enanta Pharmaceuticals, Inc (ENTA) Fair Value & Analysis

Healthcare · US · Market cap $368M

Price$14.06
Fair Value$10.02
Upside-28.7%
Quality95/100
Evidence: Low Range $7.51 – $12.52

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Enanta Pharmaceuticals, Inc (ENTA) currently trades at $14.06, while our model-based Fair Value estimate is $10.02 — implying the stock looks roughly 28.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartere…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Enanta Pharmaceuticals, Inc (ENTA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $10.02 versus a price of $14.06 — about −29% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ENTA?
Our 21-model fair value for Enanta Pharmaceuticals, Inc is $10.02 (as of Jun 24, 2026), built from audited fundamentals. The current price is $14.06.
What is the quality score of ENTA?
Enanta Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.